METTL3-mediated m6A modification increases Hspa1a stability to inhibit osteoblast aging

Yaobin Wang,Yi Chen,Hefang Xiao,Zhongcheng Liu,Xuening Liu,Zhiwei Feng,Xiaoyun Sheng,Bo Peng,Xiaojun Ren,Lihu Xu,Fei Teng,Zhi Yi,YongKang Niu,Dejian Xiang,Yayi Xia,Bin Geng
DOI: https://doi.org/10.1038/s41420-024-01925-4
2024-03-28
Cell Death Discovery
Abstract:Senile osteoporosis is mainly caused by osteoblasts attenuation, which results in reduced bone mass and disrupted bone remodeling. Numerous studies have focused on the regulatory role of m6A modification in osteoporosis; however, most of the studies have investigated the differentiation of bone marrow mesenchymal stem cells (BMSCs), while the direct regulatory mechanism of m6A on osteoblasts remains unknown. This study revealed that the progression of senile osteoporosis is closely related to the downregulation of m6A modification and methyltransferase-like 3 (METTL3). Overexpression of METTL3 inhibits osteoblast aging. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) revealed that METTL3 upregulates the stability of Hspa1a mRNA, thereby inhibiting osteoblast aging. Moreover, the results demonstrated that METTL3 enhances the stability of Hspa1a mRNA via m6A modification to regulate osteoblast aging. Notably, YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) participates in stabilizing Hspa1a mRNA in the METTL3-mediated m6A modification process, rather than the well-known degradation function. Mechanistically, METTL3 increases the stability of Hspa1a mRNA in a YTHDF2-dependent manner to inhibit osteoblast aging. Our results confirmed the significant role of METTL3 in osteoblast aging and suggested that METTL3 could be a potential therapeutic target for senile osteoporosis.
cell biology
What problem does this paper attempt to address?
The problem this paper attempts to address is: Senile osteoporosis is primarily caused by the decreased function of osteoblasts, leading to reduced bone mass and disrupted bone remodeling. Although many studies have focused on the regulatory role of m6A modification in osteoporosis, most of them have concentrated on the differentiation of bone marrow mesenchymal stem cells (BMSCs), and the direct regulatory mechanism of m6A on osteoblasts remains unclear. Specifically, this study aims to reveal the following points: 1. **Changes in m6A modification and METTL3 in senile osteoporosis**: The study found that the level of m6A modification in the bone tissue of patients with senile osteoporosis is decreased, particularly the downregulation of METTL3 expression. 2. **The effect of METTL3 on osteoblast senescence**: Overexpression of METTL3 can inhibit the senescence of osteoblasts. 3. **METTL3 regulates the stability of Hspa1a mRNA through m6A modification**: METTL3 increases the stability of Hspa1a mRNA through m6A modification, thereby inhibiting the senescence of osteoblasts. 4. **The role of YTHDF2 in the METTL3-mediated m6A modification process**: YTHDF2 is involved in stabilizing Hspa1a mRNA, rather than its known degradation function. In summary, this study reveals the mechanism by which METTL3 inhibits osteoblast senescence by regulating the stability of Hspa1a mRNA through m6A modification, providing a new potential target for the treatment of senile osteoporosis.